

rel-3-{4-[(4a*R*,7a*S*)-hexahydrocyclopenta[*b*][1,4]oxazin-4(4a*H*)-yl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzonitrile;
 4-[5-(3-cyanophenyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl]morpholine-2-carbonitrile;
 3-[4-(2,2-dimethylmorpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]benzonitrile;
 5-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]thiophene-2-carbonitrile;
 5-(imidazo[1,2-*b*]pyridazin-3-yl)-4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine;
 2-fluoro-3-{4-[2(*R*)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzonitrile;
 2-fluoro-3-{4-[2(*S*)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzonitrile;
 6-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]pyridine-2-carboxamide;
 4-(morpholin-4-yl)-5-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine;
 1-methyl-4-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-1*H*-pyrrole-2-carbonitrile;
 5-(6-methylimidazo[2,1-*b*][1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine;
 3-{4-[2-(1,2-oxazol-5-yl)morpholin-4-yl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzonitrile;
 1-methyl-4-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-1*H*-imidazole-2-carbonitrile;
 4-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]thiophene-2-carbonitrile;
 4-(morpholin-4-yl)-5-(pyrazolo[1,5-*a*]pyridin-3-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine;
 1,5-dimethyl-4-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-1*H*-pyrrole-2-carbonitrile;
 1-methyl-3-[4-(morpholin-4-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl]-1*H*-pyrazole-5-carbonitrile; and
 3-{4-[2-(cyanomethyl)morpholin-4-yl]-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl}benzonitrile;
 or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.

18. ~~A method of treating Parkinson's disease in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a~~

~~compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16.~~ A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16 for use in the treatment of Parkinson's disease in a patient.

19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16 for use in the treatment of Parkinson's disease.